Andrea DiFabio - 09 Jan 2026 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Legal Officer
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
09 Jan 2026
Net transactions value
$0
Form type
4
Filing time
09 Jan 2026, 18:52:14 UTC
Previous filing
13 Mar 2025
Next filing
11 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DiFabio Andrea Chief Legal Officer 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA /s/ Nathaniel Adams, Attorney-in-fact 09 Jan 2026 0001692506

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Share Option (Right to Buy) Award $0 +80,000 $0.000000 80,000 09 Jan 2026 Common Shares 80,000 $42.15 Direct F1
transaction XENE Restricted Share Units Award $0 +15,000 $0.000000 15,000 09 Jan 2026 Common Shares 15,000 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
F2 Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027.